普拉克索治疗不宁腿综合征临床研究  

Clinical study of pramipexole in the treatment of restless leg syndrome

作　　者：高畅[1] 傅小玲[1] 楚勤英[1] 李建华[1] 舒刚明[1] 

机构地区：[1]中国人民解放军总医院第一附属医院干二科,北京100043

出　　处：《中日友好医院学报》2016年第5期279-282,共4页Journal of China-Japan Friendship Hospital

摘　　要：目的:探讨普拉克索治疗不宁腿综合征的临床疗效。方法:选择原发性不宁腿综合征患者60例,随机分为研究1组和对照1组。选择伴有不宁腿综合征的帕金森病患者67例,随机分为研究2组和对照2组。对照1组给予氯硝西泮治疗,研究1组给予氯硝西泮+普拉克索治疗;对照2组给予多巴丝肼治疗,研究2组给予多巴丝肼+普拉克索治疗。利用国际不宁腿综合征自评量表(IRLSSG)、匹兹堡睡眠质量指数(PSQI)、汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评估治疗前后患者症状改善情况,并对患者的疗效进行比较。结果:研究1组与对照1组相比、研究2组与对照2组相比,IRLSSG、PSQI、HAMA、HAMD评分均下降显著,研究组治疗总有效率显著高于相应对照组。结论:普拉克索可有效治疗原发性不宁腿综合征及帕金森病合并不宁腿综合征,且无明显不良反应。Objective：To explore the efficacy of pramipexole in the treatment of restless leg syndrome（RLS）patients.Methods：Sixty primary RLS patients were randomly divided into two groups.They were treated with clonazepam（control group 1,n=30）or pramipexole combined with clonazepam（research group 1,n=30）.The other67 Parkinson＇s disease（PD）patients with RLS were randomly divided into two groups and treated with levodopa and benserazide hydrochloride（control group 2,n=33）or with pramipexole combined with levodopa and benserazide hydrochloride（research group 2,n =34）.International RLS study group scale（IRLSSG）,Pittsburgh sleep quality index（PSQI）,Hamilton anxiety scale（HAMA）and Hamilton depression scale（HAMD）scores were used to record the symptoms before and after the treatment to compare the efficacy.Results：Compared with control groups,IRLSSG,PSQI,HAMA,HAMD scores in research groups decreased significantly both in patients with primary RLS and those with PD and RLS.The total effective rates of research groups were significantly higher than those of the control groups.Conclusion：Pramipexole can improve the clinical symptoms of primary RLS patients and PD patients with RLS without severe side effects.

关 键 词：不宁腿综合征 帕金森病 普拉克索 

分 类 号：R741[医药卫生—神经病学与精神病学]